Towards a Treatment for Leukodystrophy Using Cell-Based Interception and Precision Medicine.
POLR3-related leukodystrophy (POLR3-HLD)
SCoPE2-MS
cell-based interception and precision medicine
induced pluripotent stem cells
leukodystrophy
proteomics
single-cell technologies
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
17 Jul 2024
17 Jul 2024
Historique:
received:
23
05
2024
revised:
12
07
2024
accepted:
14
07
2024
medline:
27
7
2024
pubmed:
27
7
2024
entrez:
27
7
2024
Statut:
epublish
Résumé
Cell-based interception and precision medicine is a novel approach aimed at improving healthcare through the early detection and treatment of diseased cells. Here, we describe our recent progress towards developing cell-based interception and precision medicine to detect, understand, and advance the development of novel therapeutic approaches through a single-cell omics and drug screening platform, as part of a multi-laboratory collaborative effort, for a group of neurodegenerative disorders named leukodystrophies. Our strategy aims at the identification of diseased cells as early as possible to intercept progression of the disease prior to severe clinical impairment and irreversible tissue damage.
Identifiants
pubmed: 39062571
pii: biom14070857
doi: 10.3390/biom14070857
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM